The purpose of this clinical trial is to assess the safety and efficacy of an investigational vaccine (a vaccine not yet approved by a country’s drug regulatory agency) aimed at preventing RSV infection in women and men over 60.
There are currently no approved treatments or vaccines for RSV. Moderna is sponsoring a clinical trial for mRNA-1345, an investigational vaccine. Moderna is studying this vaccine to understand whether it can help your body’s immune system protect against RSV.
The total length of participation in this clinical trial is approximately 2 years (25 months). It includes up to 8 trial visits and 20 brief communications (via telephone).
Reimbursement for travel and your time will be provided, and all study doctor visits will be free of charge.